184results about "Bacterial antigen ingredients" patented technology

The application discloses a new Bartonella species DGB1 derived from chicken skin mite and application of the Bartonella species DGB1 in prevention and treatment of chicken skin mite. Bartonella sp. The application provides a new Bartonella species, specifically a Bartonella DGB1, which is registered and listed in the China General Microbiological Culture Collection Center with a registration number of CGMCC No. 36714. The application also provides a Bartonella inactivated bacteria solution and an inactivated vaccine prepared from the Bartonella. The Bartonella inactivated vaccine provided by the application can effectively prevent and control chicken skin mite.

Provided herein are compositions comprising liposomes containing compound A(A) (wherein n is 1(IMM60), 2(IMM70), or 3(IMM80)), or a salt, ester, solvate, or hydrate thereof, and two or more lipids or salts thereof, and uses thereof, including methods for stimulating an immune response. Furthermore, the present invention provides a liposome comprising at least one therapeutic agent and a phospholipid bilayer comprising at least two phospholipids selected from 1,2-distearoyl-sn-glycero-3-phospho-rac-glycerol (DSPG), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and 1,2-dipalmitoyl-sn-glycero-[phosphol-rac-(1-glycerol)] (DPPG), wherein the phospholipids substantially lack cholesterol, plant sterols, and polyethylene glycolate lipids (PEG lipids).

The present invention relates to RNA-containing vaccine compositions for inducing an immune response to Porphyromonas gulae in a subject, and uses thereof.

An immunogenic complex comprising i) an amino acid sequence of an N-terminal region of a group B Streptococcus surface protein selected from the group consisting of: a first amino acid sequence according to SEQ ID NO: 16, or an amino acid sequence having at least 98%, such as 99%, identity thereto; a second amino acid sequence according to SEQ ID NO: 18 or an amino acid sequence having at least 98%, such as 99%, identity thereto; and a third amino acid sequence according to SEQ ID NO: 20; and ii) a capsular polysaccharide, is provided. An immunogenic product, a vaccine, and the immunogenic complex, the immunogenic product or the vaccine for use in a method of preventing or treating a group B Streptococcus infection, are also provided.

The present invention relates to a recombinant vaccine comprising a PIV5-based viral expression vector with a genetic insert, and methods of producing and using the same. The recombinant vaccine comprises a modified bacterial or viral antigen to increase expression of the antigen on the surface of cells (AOS) to increase immunogenicity to the antigen.

Disclosed are an mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one early-secreted antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof; PE / PPE family antigen WAG22 of Mycobacterium tuberculosis or an immunologically active fragment thereof; and at least one latent-related antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which may serve as a prophylactic vaccine for preventing latent activation or as a therapeutic drug for treating active tuberculosis, exhibiting a significant inhibitory effect on Mycobacterium tuberculosis.

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

This invention provides modified proteins, immunogenic compositions, and vaccines containing modified proteins, their manufacture, and the use of such compositions in pharmaceuticals. [Solution] A modified EPA (Exotoxin A of Pseudomonas aeruginosa) protein containing a specific amino acid sequence is provided, which is modified in that it contains one (or more) consensus sequences selected from three specific amino acid sequences, and can be used as a carrier protein for other antigens, particularly monosaccharide antigens, or other antigens lacking a T cell epitope.

The present application belongs to the field of control of pathogenic microorganisms and preparation of vaccines in aquaculture, and particularly relates to a method for preparing a bacterial pathogen inactivated vaccine based on irradiation technology and application. The present application adopts electron beam irradiation of pathogenic Aeromonas hydrophila to prepare a vaccine for preventing and treating Aeromonas hydrophila. The electron beam irradiation technology can inactivate the pathogenic bacteria in several minutes, maximally maintain the antigen conformation, realize complete removal of pathogenicity, and improve the immune recognition efficiency. The preparation method is safe, efficient, controllable, environmentally friendly, and has good industrialization expansion potential.

The invention relates to methods and compositions for preventing or treating a neuropathology in a subject associated with or induced or caused by a P. gingivalis infection, preventing the deposition of or reducing the level of P. gingivalis gingipain in neuronal tissue, delaying the onset of a P. gingivalis-induced or associated neuropathology, for preventing or slowing the rate of abnormal protein deposition in the neuronal tissue, and / or reducing neuroinflammation, the methods comprising administering an RNA polynucleotide encoding a protein comprising or consisting of: - one or more amino acid sequences of an active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and / or - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto, wherein the polynucleotide is capable of being translated in a mammalian cell.

The present invention relates to the use of a therapeutic agent based on cell wall fragments of a virulent strain of Mycobacterium tuberculosis-complex for the preparation of a drug for the treatment of patients with active tuberculosis.

The present disclosure provides formulations, kits, and vaccines directed to immunization of animals against Salmonella. Methods of usng the formulations, kits, and vaccines for protection of avians against one or more species of Salmonella are also provided.

The present disclosure relates to a BCG based therapeutic agent using a BCG strain that overexpresses the STING agonist, c-di-AMP. This BCG strain, called BCG-disA-OE, enhances the elevated trained immunity of macrophages and promotes early anti-viral Type I interferon responses in a subject, providing protection against viral infections such as primary respiratory infections and SARS-CoV-2 infection.

In one aspect, the disclosure relates to pneumococcal vaccines comprising a semisynthetic saponin adjuvant VSA-1. In one aspect, the disclosed vaccines elicit an immune response in a subject that is measurably higher than the response in an otherwise identical subject who receives a vaccine without the semisynthetic saponin adjuvant. In another aspect, the disclosed vaccines are useful across age groups and immunization can be achieved with fewer injections than for standard pneumococcal vaccines. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The present invention relates to a combination of a first vaccine containing a non-replicating immunogen of Erysipelothrix rhusiopathiae and a non-replicating immunogen of porcine parvovirus, and a second vaccine containing a non-replicating immunogen of Leptospira bacteria, for use in the prophylactic treatment of pigs against Erysipelothrix rhusiopathiae infection, porcine parvovirus infection, and Leptospira bacteria infection, by injecting the first vaccine and the second vaccine separately into the dermis at a first injection site and a second injection site, respectively, in association with each other.

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

The present invention relates to novel compounds and formulations. Additionally, the present invention relates to novel compounds and formulations useful for pneumococcal and pneumococcal conjugate vaccines. More specifically, the present invention relates to compositions comprising a pneumococcal conjugate and one or more compounds of Formula I, Ia, II, IIa, III, IIIa, IV, or IVa, or pharmaceutically acceptable salts thereof, formulated as a stable nanoemulsion (referred to herein as an "SNE adjuvant composition" or "SNE").

To provide immunogenic compositions capable of providing appropriate protection against Streptococcus pneumoniae serotypes not found in conventional vaccines.SOLUTION: The present invention provides new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR, SYNFLORIX and / or PREVNAR 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using the novel immunogenic compositions.SELECTED DRAWING: Figure 1

This invention provides a live attenuated Brucella vaccine strain M5Δ pyrE Its construction methods and applications belong to the field of biotechnology. The M5... pyrE The strain was obtained by knocking out Brucella mesenteriae strain M5. pyrE Genetically constructed and deposited at the China Center for Type Culture Collection. This invention discovers that... pyrE The gene is associated with Brucella virulence; knocking out this gene significantly weakens Brucella virulence and reduces its intracellular and mouse viability. Compared to the existing vaccine strain M5-9026, M5... pyrE The strain exhibits superior immunoprotective effects, effectively inducing humoral and Th1 cellular immune responses, and demonstrates good safety. The M5 strain constructed in this invention... pyrE This strain has promising potential as a candidate strain for a live attenuated vaccine to prevent brucellosis in animals.

The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.

The present invention relates to compositions or vaccines for combating Mycoplasma hyopneumoniae (M hyo), Porcine Circovirus type 2 (PCV2), and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infections in animals and for increasing the ability of pigs to gain weight and / or improve death loss, methods of vaccination against the infections, and kits for use with such methods and compositions.

The present invention is directed to a vaccine composition against a disease caused by Mycobacterium tuberculosis, said composition comprising at least four nucleic acids selected from the following groups: a. a nucleic acid encoding an Ag85A, Ag85B, or Ag85C antigen; b. a nucleic acid encoding a resuscitation promoting factor (Rpf) selected from the group consisting of: RpfA, RpfB, RpfC, RpfD and RpfE; c. a nucleic acid encoding a PE / PPE antigen selected from the group consisting of: PE5, PE13, PE15, PE29, PE31, PPE1, PPE2, PPE18, PPE20, and PPE68; d. a nucleic acid encoding a disease-reactivation-related antigen selected from the group consisting of: Rv1234 / MMAR_4207, and Rv0359 / MMAR_0678, wherein said vaccine composition comprises at least one nucleic acid from each of group a, b, and c; and wherein the nucleic acids are provided on one or more nucleic acids constructs.

The present invention relates to RNA-containing vaccine compositions for inducing an immune response to Porphyromonas gingivalis in a subject, and uses thereof.

The disclosure relates to the identification and characterisation of a cytotoxin from Campylobacter hepaticus and use thereof for treating Spotty Liver Disease (SLD) in avian animals.

The technology proposed herein concerns a vaccine formulation comprising a) an antigen comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, and b) a buffer having a pH of 6 to 8 and comprising: a. aluminum hydroxide gel particles, and b. a buffer system comprising: i. 1-3 mM phosphate and 100-200 mM NaCl, or ii. 5-15 mM histidine and 200-400 mM sorbitol. The technology proposed herein further concerns a method of producing a vaccine formulation as well as a vaccine formulation for use in a method of reducing, preventing and / or treating a GBS infection.

The present disclosure relates to methods of producing a 900 kDa BoNT / A complex, wherein the method does not comprise a step of precipitation during the purification process. Further provided herein are methods of preparing a Clostridium botulinum working cell bank (WCB).

This application discloses a composition, a method for preparing the composition, and its application, comprising: an mRNA molecule containing a first sequence; and an LNP nanoparticle delivery carrier; wherein the protein encoded by the first sequence has BP26 protein immunogenicity, the first sequence encodes a first amino acid sequence, the first amino acid sequence includes multiple sub-sequences in tandem, the multiple sub-sequences being selected from the amino acid sequences corresponding to T cell and B cell recognition epitopes in wild-type BP26 protein, and the composition has high immunogenicity and high targeting against Brucella.

A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.

The invention belongs to the technical field of biological medicine, and particularly relates to a PDHC mutant, an immunogenic fragment and application, the PDHC mutant has amino acid mutation at at least one of the 214th site, the 274th site or the 294th site of the amino acid sequence shown in SEQ ID NO: 1, and the PDHC mutant is used for preventing or treating staphylococcus aureus (SA) infection and is an mRNA vaccine for preventing or treating staphylococcus aureus (SA) infection. The stability and immunogenicity of the staphylococcus aureus PDHC antigen are greatly improved, efficient targeted delivery of the antigen is achieved, and the immune effect of the vaccine is remarkably improved.